JGC
REGN icon

J. Goldman & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

J. Goldman & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.32M Sell
6,936
-9,332
-57% -$6.35M 0.11% 224
2026
Q1 		$12.6M Buy
16,268
+9,916
+156% +$7.59M 0.37% 79
2025
Q4 		$4.9M Sell
6,352
-14,914
-70% -$10.1M 0.13% 200
2025
Q3 		$12M Sell
21,266
-12,580
-37% -$7.11M 0.3% 105
2025
Q2 		$17.8M Buy
33,846
+18,960
+127% +$10.6M 0.43% 72
2025
Q1 		$9.44M Buy
14,886
+2,298
+18% +$1.58M 0.23% 133
2024
Q4 		$8.97M Buy
12,588
+3,694
+42% +$3.1M 0.23% 129
2024
Q3 		$9.35M Buy
8,894
+3,208
+56% +$3.57M 0.26% 110
2024
Q2 		$5.98M Sell
5,686
-912
-14% -$884K 0.17% 158
2024
Q1 		$6.35M Sell
6,598
-39,005
-86% -$37.1M 0.2% 132
2023
Q4 		$40.1M Sell
45,603
-17
-0% -$14K 1.62% 8
2023
Q3 		$37.5M Buy
45,620
+25,814
+130% +$20.3M 1.32% 13
2023
Q2 		$14.2M Buy
19,806
+17,759
+868% +$13.7M 0.52% 59
2023
Q1 		$1.68M Sell
2,047
-19,854
-91% -$15M 0.07% 216
2022
Q4 		$15.8M Buy
21,901
+17,867
+443% +$13.2M 0.78% 37
2022
Q3 		$2.78M Sell
4,034
-825
-17% -$519K 0.13% 179
2022
Q2 		$2.87M Buy
+4,859
New +$3.16M 0.14% 171

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

J. Goldman & Co's REGN Position: Q2 2026 in Review

J. Goldman & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 57% in Q2 2026, selling an estimated $6.35M and leaving 6,936 shares worth $4.32M. The position accounts for 0.11% of the portfolio, ranked #224.

J. Goldman & Co first reported a position in REGN in Q2 2022 and has held it in 17 quarters since. The position peaked at $40.1M in Q4 2023. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • J. Goldman & Co held 6,936 shares of Regeneron Pharmaceuticals worth $4.32M as of Q2 2026.
  • J. Goldman & Co sold 9,332 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.35M.
  • Regeneron Pharmaceuticals made up 0.11% of J. Goldman & Co's portfolio in Q2 2026, its #224 holding.
  • J. Goldman & Co first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • J. Goldman & Co's Regeneron Pharmaceuticals position peaked at $40.1M in Q4 2023.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.